A CYP7A1 CYP7A1 1.2 1.2 AICAR (2 mM) 1.0 1.0 0.8 * 0.8 mRNA expression 0.6 mRNA expression * 0.6 0.4 0.4 * * 0.2 0.2 AICAR (mM) - 1 2 0h 2h 6h 24h B CYP27A1 CYP27A1 1.2 1.4 AICAR (2 mM) 1.0 1.2 1.0 0.8 0.8 mRNA expression 0.6 mRNA expression 0.6 0.4 0.4 0.2 0.2 AICAR (mM) - 1 2 0h 2h 6h 24h C. HNF4 HNF4 1.2 1.4 1.2 1.0 1.0 0.8 mRNA expression 0.8 mRNA expression 0.6 0.6 0.4 0.4 0.2 0.2 AdGFP AdAMPKα2 Ad DN-AMPK AICAR(mM) - 1 2 Supplemental Fig 1. HepG2 cells were treated with AICAR for time periods and doses indicated, or infected with Ad-GFP, Ad-AMPKα2 or Ad-DN-AMPK at an MOI of ~ 10 for 24 hr. mRNA expressions were determined by real-time PCR in triplicates and expressed as mean ± S.D.
ChREBP mRNA expression Sicon siACL siAceCS1 5.5 mM 27.7 mM ChREBP 1 2 3 4 5 6 * Supplemental Fig 2. HepG2 cells were transfected with siCon, siACL or siAceCS1 and treated with 5.5 or 27.5 mM glucose for 24 hr as described in Materials and Methods. The mRNA expression levels were determined by real-time PCR.